Aquestive Therapeutics (AQST) Competitors $4.44 -0.13 (-2.84%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AQST vs. XERS, CHMA, OPTN, CMRX, FBIO, GLPG, NTLA, IMCR, EVO, and OCULShould you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Xeris Biopharma (XERS), Chiasma (CHMA), OptiNose (OPTN), Chimerix (CMRX), Fortress Biotech (FBIO), Galapagos (GLPG), Intellia Therapeutics (NTLA), Immunocore (IMCR), Evotec (EVO), and Ocular Therapeutix (OCUL). These companies are all part of the "medical" sector. Aquestive Therapeutics vs. Xeris Biopharma Chiasma OptiNose Chimerix Fortress Biotech Galapagos Intellia Therapeutics Immunocore Evotec Ocular Therapeutix Aquestive Therapeutics (NASDAQ:AQST) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Does the media favor AQST or XERS? In the previous week, Xeris Biopharma had 15 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 20 mentions for Xeris Biopharma and 5 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.41 beat Xeris Biopharma's score of 0.33 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xeris Biopharma 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in AQST or XERS? 32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 7.9% of Aquestive Therapeutics shares are held by company insiders. Comparatively, 4.6% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, AQST or XERS? Aquestive Therapeutics has a beta of 2.82, indicating that its share price is 182% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.7, indicating that its share price is 170% more volatile than the S&P 500. Do analysts recommend AQST or XERS? Aquestive Therapeutics presently has a consensus target price of $9.80, indicating a potential upside of 120.72%. Xeris Biopharma has a consensus target price of $4.87, indicating a potential upside of 66.67%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aquestive Therapeutics is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community believe in AQST or XERS? Aquestive Therapeutics received 67 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.76% of users gave Xeris Biopharma an outperform vote while only 67.96% of users gave Aquestive Therapeutics an outperform vote. CompanyUnderperformOutperformAquestive TherapeuticsOutperform Votes21067.96% Underperform Votes9932.04% Xeris BiopharmaOutperform Votes14369.76% Underperform Votes6230.24% Is AQST or XERS more profitable? Xeris Biopharma has a net margin of -33.69% compared to Aquestive Therapeutics' net margin of -59.75%. Aquestive Therapeutics' return on equity of 0.00% beat Xeris Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics-59.75% N/A -33.96% Xeris Biopharma -33.69%-16,662.63%-17.38% Which has preferable earnings & valuation, AQST or XERS? Aquestive Therapeutics has higher earnings, but lower revenue than Xeris Biopharma. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquestive Therapeutics$50.58M8.00-$7.87M-$0.45-9.87Xeris Biopharma$163.91M2.66-$62.26M-$0.45-6.49 SummaryAquestive Therapeutics beats Xeris Biopharma on 12 of the 19 factors compared between the two stocks. Ad Darwin2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQST vs. The Competition Export to ExcelMetricAquestive TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$404.84M$6.49B$5.13B$8.74BDividend YieldN/A8.15%5.18%4.07%P/E Ratio-9.874.8266.7313.27Price / Sales8.00374.171,265.2981.14Price / CashN/A51.8140.2135.77Price / Book-8.889.636.455.92Net Income-$7.87M$154.43M$119.73M$225.73M7 Day Performance-18.68%-9.46%-5.13%-1.34%1 Month Performance-9.76%-7.27%-2.71%1.15%1 Year Performance156.65%28.13%31.08%24.02% Aquestive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQSTAquestive Therapeutics1.987 of 5 stars$4.44-2.8%$9.80+120.7%+158.1%$404.84M$50.58M-9.87160Short Interest ↓XERSXeris Biopharma4.0134 of 5 stars$3.28-5.5%N/A+86.0%$488.72M$181.41M-7.29290Analyst RevisionNews CoverageCHMAChiasmaN/A$3.76flatN/A+0.0%$217.68M$1.11M-2.3485OPTNOptiNose3.9652 of 5 stars$0.77-1.3%N/A-65.2%$115.83M$70.99M-2.13190Analyst ForecastAnalyst RevisionNews CoverageCMRXChimerix4.4465 of 5 stars$1.04+5.1%N/A-14.0%$93.23M$320,000.00-1.1172Short Interest ↓FBIOFortress Biotech3.1706 of 5 stars$1.76+2.9%N/A+0.0%$40.15M$84.51M-0.54186Analyst DowngradeNews CoverageGLPGGalapagos1.6033 of 5 stars$27.98+3.4%N/A-27.5%$1.84B$259.40M0.001,123Short Interest ↓High Trading VolumeNTLAIntellia Therapeutics4.5317 of 5 stars$17.50+4.6%N/A-46.3%$1.78B$36.28M-3.22600Gap UpIMCRImmunocore2.9264 of 5 stars$34.64-0.1%N/A-32.6%$1.73B$296.31M-36.46497Gap DownEVOEvotec1.0235 of 5 stars$4.87+17.9%N/A-44.7%$1.73B$845.74M0.005,061Short Interest ↓News CoverageGap UpHigh Trading VolumeOCULOcular Therapeutix4.0252 of 5 stars$10.96-1.3%N/A+340.4%$1.71B$58.44M-8.12267Analyst ForecastNews Coverage Related Companies and Tools Related Companies XERS Alternatives CHMA Alternatives OPTN Alternatives CMRX Alternatives FBIO Alternatives GLPG Alternatives NTLA Alternatives IMCR Alternatives EVO Alternatives OCUL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AQST) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AQST Stock Alerts